Your browser is no longer supported. Please, upgrade your browser.
Settings
VIVO [NASD]
Meridian Bioscience, Inc.
Index- P/E11.53 EPS (ttm)1.61 Insider Own1.20% Shs Outstand43.10M Perf Week-3.82%
Market Cap752.59M Forward P/E14.62 EPS next Y1.27 Insider Trans-30.22% Shs Float42.87M Perf Month-22.52%
Income70.10M PEG0.68 EPS next Q0.33 Inst Own- Short Float9.75% Perf Quarter-33.18%
Sales299.20M P/S2.52 EPS this Y88.20% Inst Trans12.68% Short Ratio5.13 Perf Half Y-0.37%
Book/sh6.47 P/B2.88 EPS next Y-23.31% ROA11.80% Target Price32.67 Perf Year2.70%
Cash/sh1.56 P/C11.91 EPS next 5Y17.00% ROE19.20% 52W Range12.98 - 30.65 Perf YTD-0.43%
Dividend- P/FCF16.84 EPS past 5Y4.80% ROI15.20% 52W High-39.28% Beta0.49
Dividend %- Quick Ratio2.10 Sales past 5Y5.40% Gross Margin63.60% 52W Low43.37% ATR1.16
Employees560 Current Ratio3.30 Sales Q/Q96.00% Oper. Margin20.50% RSI (14)31.37 Volatility6.66% 4.66%
OptionableYes Debt/Eq0.00 EPS Q/Q829.10% Profit Margin15.40% Rel Volume0.64 Prev Close18.51
ShortableYes LT Debt/Eq0.21 EarningsMay 07 BMO Payout0.00% Avg Volume814.34K Price18.61
Recom1.50 SMA20-12.71% SMA50-20.18% SMA200-9.54% Volume518,744 Change0.54%
Aug-11-20Resumed Piper Sandler Overweight $24
Jul-27-20Initiated H.C. Wainwright Buy $34
May-11-20Upgrade William Blair Mkt Perform → Outperform
May-01-19Upgrade Piper Jaffray Underweight → Neutral $15 → $11
Apr-03-19Downgrade Canaccord Genuity Hold → Sell $17 → $11
Jan-26-18Reiterated Canaccord Genuity Hold $14 → $16
Mar-28-17Initiated CL King Neutral
Mar-28-16Reiterated Canaccord Genuity Hold $18 → $19
Sep-10-15Reiterated Canaccord Genuity Hold $19 → $18
Jul-27-15Reiterated Canaccord Genuity Hold $20 → $19
May-04-15Reiterated Canaccord Genuity Hold $19 → $20
Nov-06-14Downgrade Robert W. Baird Outperform → Neutral $22 → $22
Jul-27-12Downgrade Canaccord Genuity Buy → Hold
Apr-25-11Upgrade Wedbush Underperform → Neutral $18 → $22
Mar-24-11Upgrade Canaccord Genuity Hold → Buy $30
Nov-16-10Initiated Canaccord Genuity Hold $21
Apr-07-10Initiated Wedbush Underperform $18
Nov-13-09Reiterated Caris & Company Average $21 → $20
Jul-07-09Initiated Caris & Company Average $21
Mar-06-09Initiated William Blair Mkt Perform
May-07-21 05:45PM  
01:01PM  
08:50AM  
07:45AM  
07:30AM  
Apr-30-21 03:00PM  
Apr-28-21 05:45PM  
02:00PM  
Apr-21-21 05:45PM  
Apr-19-21 02:00PM  
Apr-14-21 05:45PM  
07:35AM  
Apr-05-21 07:27AM  
Apr-01-21 09:13AM  
09:00AM  
Mar-31-21 03:25PM  
Mar-29-21 11:30AM  
Mar-25-21 10:30PM  
Mar-24-21 09:59AM  
03:05AM  
Mar-22-21 09:29AM  
05:20AM  
Mar-21-21 09:54PM  
Mar-18-21 04:58PM  
09:59AM  
06:43AM  
Mar-17-21 06:27AM  
Mar-16-21 10:15PM  
Mar-14-21 09:46PM  
Mar-12-21 11:30AM  
06:00AM  
Mar-11-21 09:15AM  
Mar-09-21 10:30PM  
06:10AM  
Mar-08-21 10:52AM  
10:00AM  
Mar-07-21 06:02PM  
Mar-04-21 09:00AM  
Mar-01-21 12:45PM  
Feb-23-21 02:30PM  
01:47PM  
01:16PM  
08:00AM  
Feb-22-21 01:06PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
04:35PM  
Feb-16-21 08:00AM  
Feb-12-21 12:45PM  
11:16AM  
09:28AM  
Feb-11-21 04:15PM  
09:01AM  
08:27AM  
05:40AM  
05:20AM  
Feb-10-21 09:26AM  
09:14AM  
Feb-09-21 09:56AM  
09:41AM  
Feb-08-21 11:30AM  
Feb-05-21 02:01PM  
08:45AM  
08:15AM  
07:47AM  
07:30AM  
Feb-04-21 08:40AM  
Feb-03-21 10:30AM  
Feb-02-21 09:41AM  
08:00AM  
Jan-29-21 05:50PM  
09:59AM  
Jan-28-21 08:02AM  
Jan-27-21 10:42AM  
Jan-21-21 05:50PM  
Jan-20-21 12:10PM  
Jan-19-21 09:56AM  
Jan-14-21 05:50PM  
Jan-13-21 04:30PM  
Jan-12-21 08:03AM  
Jan-11-21 07:09AM  
Jan-08-21 11:12AM  
09:12AM  
06:48AM  
05:54AM  
05:20AM  
Jan-07-21 08:19AM  
08:00AM  
Jan-06-21 09:30AM  
Jan-05-21 12:20PM  
Dec-31-20 11:30AM  
Dec-29-20 03:31PM  
06:55AM  
Dec-28-20 07:59AM  
Dec-18-20 01:12AM  
Dec-17-20 10:28AM  
Dec-16-20 03:00PM  
Dec-14-20 10:34AM  
07:19AM  
Dec-11-20 07:58AM  
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kenny John P.Chief Executive OfficerMar 17Sale25.0030,000750,000208,659Mar 18 08:37 AM
Kenny John P.Chief Executive OfficerMar 10Sale25.0010,000250,000238,659Mar 11 04:29 PM
Kenny John P.Chief Executive OfficerFeb 16Option Exercise10.102,08221,028251,018Feb 17 10:14 AM
Kenny John P.Chief Executive OfficerFeb 16Sale30.352,35971,604248,659Feb 17 10:14 AM
Kenny John P.Chief Executive OfficerFeb 12Option Exercise10.1023,097233,280275,117Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 12Sale30.1426,181789,085248,936Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 11Option Exercise10.101,16411,756253,340Feb 16 08:45 AM
Kenny John P.Chief Executive OfficerFeb 11Sale30.001,32039,601252,020Feb 16 08:45 AM
Rice John McCune Jr.DirectorFeb 08Option Exercise11.6027,205315,46440,917Feb 09 03:02 PM
Baldasare Bryan TExec VP & CFOFeb 08Option Exercise19.563,75073,35062,382Feb 09 01:26 PM
Kenny John P.Chief Executive OfficerFeb 08Option Exercise13.4366,134887,953320,464Feb 10 01:22 PM
Baldasare Bryan TExec VP & CFOFeb 08Sale30.006,254187,62056,128Feb 09 01:26 PM
Kenny John P.Chief Executive OfficerFeb 08Sale29.8668,2882,039,114252,176Feb 10 01:22 PM
Rice John McCune Jr.DirectorFeb 08Sale28.1616,480464,00824,437Feb 09 03:02 PM
Baldasare Bryan TExec VP & CFOFeb 05Option Exercise19.5611,250220,05072,882Feb 08 10:21 AM
Baldasare Bryan TExec VP & CFOFeb 05Sale26.6114,250379,12658,632Feb 08 10:21 AM
Kenny John P.Chief Executive OfficerFeb 05Sale25.0040,0001,000,000254,330Feb 08 10:18 AM
Bihl Anthony P IIIDirectorNov 25Buy17.655,00088,26510,851Nov 30 10:47 AM
Baldasare Bryan TExec VP & CFOJun 30Option Exercise19.711,50029,56554,137Jul 02 01:52 PM